Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?
Nanoparticles bearing specific targeting groups can, in principle, accumulate exclusively at lesion sites bearing target molecules, and release therapeutic agents there. However, practical application of targeted nanoparticles in the living organism presents challenges. In particular, intravasally a...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/8932 |
id |
doaj-a18123b7e01c4e27ad95dca81264b155 |
---|---|
record_format |
Article |
spelling |
doaj-a18123b7e01c4e27ad95dca81264b1552021-08-26T13:53:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-08-01228932893210.3390/ijms22168932Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?Gudrun C. Thurner0Johannes Haybaeck1Paul Debbage2Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Müllerstraße 44, 6020 Innsbruck, AustriaInstitute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Müllerstraße 44, 6020 Innsbruck, AustriaDepartment of Anatomy, Histology and Embryology, Medical University of Innsbruck, Müllerstraße 59, 6020 Innsbruck, AustriaNanoparticles bearing specific targeting groups can, in principle, accumulate exclusively at lesion sites bearing target molecules, and release therapeutic agents there. However, practical application of targeted nanoparticles in the living organism presents challenges. In particular, intravasally applied nanoparticles encounter physical and physiological barriers located in blood vessel walls, blocking passage from the blood into tissue compartments. Whereas small molecules can pass out of the blood, nanoparticles are too large and need to utilize physiological carriers enabling passage across endothelial walls. The issues associated with crossing blood-tissue barriers have limited the usefulness of nanoparticles in clinical applications. However, nanoparticles do not encounter blood-tissue barriers if their targets are directly accessible from the blood. This review focuses on osteoporosis, a disabling and common disease for which therapeutic strategies are limited. The target sites for therapeutic agents in osteoporosis are located in bone resorption pits, and these are in immediate contact with the blood. There are specific targetable biomarkers within bone resorption pits. These present nanomedicine with the opportunity to treat a major disease by use of simple nanoparticles loaded with any of several available effective therapeutics that, at present, cannot be used due to their associated side effects.https://www.mdpi.com/1422-0067/22/16/8932osteoporosisnanoparticlestissue-barriersHowship’s lacunatargeting |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gudrun C. Thurner Johannes Haybaeck Paul Debbage |
spellingShingle |
Gudrun C. Thurner Johannes Haybaeck Paul Debbage Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? International Journal of Molecular Sciences osteoporosis nanoparticles tissue-barriers Howship’s lacuna targeting |
author_facet |
Gudrun C. Thurner Johannes Haybaeck Paul Debbage |
author_sort |
Gudrun C. Thurner |
title |
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? |
title_short |
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? |
title_full |
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? |
title_fullStr |
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? |
title_full_unstemmed |
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis? |
title_sort |
targeting drug delivery in the elderly: are nanoparticles an option for treating osteoporosis? |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-08-01 |
description |
Nanoparticles bearing specific targeting groups can, in principle, accumulate exclusively at lesion sites bearing target molecules, and release therapeutic agents there. However, practical application of targeted nanoparticles in the living organism presents challenges. In particular, intravasally applied nanoparticles encounter physical and physiological barriers located in blood vessel walls, blocking passage from the blood into tissue compartments. Whereas small molecules can pass out of the blood, nanoparticles are too large and need to utilize physiological carriers enabling passage across endothelial walls. The issues associated with crossing blood-tissue barriers have limited the usefulness of nanoparticles in clinical applications. However, nanoparticles do not encounter blood-tissue barriers if their targets are directly accessible from the blood. This review focuses on osteoporosis, a disabling and common disease for which therapeutic strategies are limited. The target sites for therapeutic agents in osteoporosis are located in bone resorption pits, and these are in immediate contact with the blood. There are specific targetable biomarkers within bone resorption pits. These present nanomedicine with the opportunity to treat a major disease by use of simple nanoparticles loaded with any of several available effective therapeutics that, at present, cannot be used due to their associated side effects. |
topic |
osteoporosis nanoparticles tissue-barriers Howship’s lacuna targeting |
url |
https://www.mdpi.com/1422-0067/22/16/8932 |
work_keys_str_mv |
AT gudruncthurner targetingdrugdeliveryintheelderlyarenanoparticlesanoptionfortreatingosteoporosis AT johanneshaybaeck targetingdrugdeliveryintheelderlyarenanoparticlesanoptionfortreatingosteoporosis AT pauldebbage targetingdrugdeliveryintheelderlyarenanoparticlesanoptionfortreatingosteoporosis |
_version_ |
1721192507629371392 |